cPass New Antibody Test

This is what this tests shows, so that you know for yourself:

Test Details
Use

Qualitative and semi-quantitative detection of antibodies to SARS-CoV-2 spike protein receptor-binding domain (RBD). Aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time it is unknown how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The performance of this test has not been established in individuals that have received a COVID-19 vaccine. The clinical significance of a positive or negative antibody result following COVID-19 vaccination has not been established and the result from this test should not be interpreted as an indication or degree of protection from infection after vaccination.
Limitations

This test should not be used to diagnose or exclude acute SARS-CoV-2 infection. The results should always be assessed in conjunction with the patient's medical history, clinical presentation, and other findings. A negative test result does not rule out the possibility of an infection with SARS-CoV-2. Serum or plasma samples from the very early (pre-seroconversion) phase can yield negative findings. Therefore, this test cannot be used to diagnose acute infection. It has also been reported that certain patients with the confirmed infection do not develop SARS-CoV-2 antibodies. Furthermore, the waning of antibody titers has been reported in some individuals within a range of months after infection, a feature which has also been reported for other coronaviruses.

This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of the declaration that circumstances exist, justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens.
Methodology

This test shows only detects that you have antibodies, but not the significance of the number or what the number means.

I just want to know my antibody level, 2 years after my one and only J&J vaccine. Kaiser(They use Stanford Healthcare Lab) only provides a positive or negative, yet their equipment is capable of readings >2500. FDA directives are suppressing release of quantitative results to the public. I did get a lab in San Jose(Target DX) to report the semi-quantitative (>250) 1year after my J&J vaccination.

The test I was given at Mayo is SARS-COV-2 SPIKE AB, SEMI-QUANT,S
Component Results: Interp. S = Positive
Quant, S = 561 U/ml
I know several people who have had this test done here at Mayo. Numbers vary but all were vaccinated early in the year.
Sorry if this does not help here......

@merpreb I think that is the test being used by JH. I know that MGH will not give me an order for an antibody test but my PCP did the last time. I hope she will again, I think it does give us some indication if that third shot has helped.
JK

@sueinmn I did have their antibody test. I went to LabCorp which is the lab they are using, and had the test that they use. This was about 5 or 6 weeks after my second shot and my antibody number was 13.83 which is pretty low. I hope my PCP will write the order for me to get it again, if not I will have to pay for it myself.
JK

LabCorp antibody test for Covid from their website:
Can semi-quantitative COVID-19 antibody test be used to track antibody levels overtime?
On May 19, 2021, the FDA issued a safety communication reiterating that “antibody testing should not be used to evaluate a person’s level of immunity or protection from COVID-19 at any time, and especially after the person received a COVID-19 vaccination.”4 Currently authorized SARS-CoV-2 antibody tests, including the SARS-CoV-2 Semi-Quantitative Total Antibody assay (164090), have not been evaluated to assess the level of protection provided by an immune response to COVID-19 vaccination. Additionally, the components of a protective immune response against infection or re-infection with SARS-CoV-2 have not been fully characterized (e.g., antibody, T cell, etc.). Clinical trials and other studies are underway to elucidate the correlates of immunity to SARS-CoV-2.

Effective March 28, 2022 Labcorp expanded the reporting range of results for test number 164090 SARS-CoV-2 Semi-Quantitative Total Antibody, Spike. Results previously reported for this assay were 0.8-2500 U/mL with higher values reported as >2500 U/mL. With the addition of an automated dilution, we are now able to report result 0.8-25000 U/mL with higher values reported as >25000 U/mL. This change does not impact previously reported results; it just increases the numerical values above 2500 U/mL that we are able to report.

Why aren't you getting this information from your doctors? I'm assuming that you have.